UA102502C2 - Antihypertensive organic salt - Google Patents
Antihypertensive organic saltInfo
- Publication number
- UA102502C2 UA102502C2 UAA200810219A UAA200810219A UA102502C2 UA 102502 C2 UA102502 C2 UA 102502C2 UA A200810219 A UAA200810219 A UA A200810219A UA A200810219 A UAA200810219 A UA A200810219A UA 102502 C2 UA102502 C2 UA 102502C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antihypertensive
- organic salt
- coo
- group
- inhibitor selected
- Prior art date
Links
- 230000003276 anti-hypertensive effect Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- -1 moexiprilate Chemical compound 0.000 abstract 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 abstract 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 abstract 1
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 abstract 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 abstract 1
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 108010007859 Lisinopril Proteins 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 abstract 1
- 229940125400 channel inhibitor Drugs 0.000 abstract 1
- 229960002680 enalaprilat Drugs 0.000 abstract 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 abstract 1
- 229960003580 felodipine Drugs 0.000 abstract 1
- 229960004427 isradipine Drugs 0.000 abstract 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 abstract 1
- 229960004340 lacidipine Drugs 0.000 abstract 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 abstract 1
- 229960002394 lisinopril Drugs 0.000 abstract 1
- ODAIHABQVKJNIY-PEDHHIEDSA-N perindoprilat Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@H]21 ODAIHABQVKJNIY-PEDHHIEDSA-N 0.000 abstract 1
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 abstract 1
- FMMDBLMCSDRUPA-BPUTZDHNSA-N spiraprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)C(O)=O)CC1=CC=CC=C1 FMMDBLMCSDRUPA-BPUTZDHNSA-N 0.000 abstract 1
- 108700006892 spiraprilat Proteins 0.000 abstract 1
- AHYHTSYNOHNUSH-HXFGRODQSA-N trandolaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 AHYHTSYNOHNUSH-HXFGRODQSA-N 0.000 abstract 1
- UQWLOWFDKAFKAP-WXHSDQCUSA-N zofenoprilat Chemical compound C1[C@@H](C(O)=O)N(C(=O)[C@@H](CS)C)C[C@H]1SC1=CC=CC=C1 UQWLOWFDKAFKAP-WXHSDQCUSA-N 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
An antihypertensive organic salt of general formula [(R1-COO-)·(+H3N-R2)], wherein (R1-COO-) is an angiotensin-converting enzyme inhibitor selected from the group comprising perindoprilate, ramiprilate, spiraprilate, benazeprilate, moexiprilate, trandolaprilate, fozinoprilate, enalaprilate, zofenoprilate or lisinopril, and (+H3N-R2) is a calcium channel inhibitor selected from the group comprising amlodipine, lacidipine, felodipine, isradipine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200810219A UA102502C2 (en) | 2008-08-08 | 2008-08-08 | Antihypertensive organic salt |
| RU2009117795/15A RU2413717C2 (en) | 2008-08-08 | 2009-05-14 | Anti-hypertension organic salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200810219A UA102502C2 (en) | 2008-08-08 | 2008-08-08 | Antihypertensive organic salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA102502C2 true UA102502C2 (en) | 2013-07-25 |
Family
ID=44058043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200810219A UA102502C2 (en) | 2008-08-08 | 2008-08-08 | Antihypertensive organic salt |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2413717C2 (en) |
| UA (1) | UA102502C2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030180355A1 (en) * | 2001-10-16 | 2003-09-25 | Amedeo Leonardi | Combination therapy for hypertension |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| KR100841409B1 (en) * | 2003-12-16 | 2008-06-25 | 에스케이케미칼주식회사 | Amlodipine gentisate salt and preparation method thereof |
-
2008
- 2008-08-08 UA UAA200810219A patent/UA102502C2/en unknown
-
2009
- 2009-05-14 RU RU2009117795/15A patent/RU2413717C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009117795A (en) | 2010-11-20 |
| RU2413717C2 (en) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007126883A3 (en) | Surveying sterilizer methods and systems | |
| SG148142A1 (en) | Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof | |
| EP1655275A3 (en) | Fertilizer composition containing calcium phosphite | |
| MX2010006736A (en) | Hcv protease inhibitors and uses thereof. | |
| TNSN08191A1 (en) | Kinase inhibitors | |
| MX2010007840A (en) | Crystalline forms of dimethoxy docetaxel and methods for preparing same. | |
| WO2009082701A8 (en) | Hcv protease inhibitors and uses thereof | |
| EP2305667A3 (en) | Nilotinib intermediates and preparation thereof | |
| IL192635A0 (en) | Cis-4,5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors | |
| ZA200802848B (en) | Potassium channel inhibitors | |
| TW200720232A (en) | Crystalline solid forms of tigecycline and methods of preparing same | |
| SG148179A1 (en) | Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors | |
| WO2008090417A3 (en) | Inhibition of nf-kb | |
| WO2009042270A3 (en) | Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity | |
| MX2009004947A (en) | Arylsulfonyl pyrrolidines as 5-ht6 inhibitors. | |
| WO2007112457A3 (en) | Aprepitant polymorph mixtures | |
| MX2008007808A (en) | Rifamycin analogs and uses thereof. | |
| WO2008156645A3 (en) | Pharmaceutical compositions and uses | |
| EP2023925A4 (en) | Cdki pathway inhibitors as selective inhibitors of tumor cell growth | |
| WO2006034035A3 (en) | Treatment of ischemia | |
| WO2010148177A3 (en) | Compounds, compositions, methods of synthesis, and methods of treatment | |
| UA102502C2 (en) | Antihypertensive organic salt | |
| IL180791A0 (en) | Benzyloxy derivatives as maob inhibitors | |
| MX2007011826A (en) | Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same. | |
| WO2010056914A8 (en) | Bacterial helicase inhibitor compounds and uses thereof |